Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China; Department of Urology, The First College of Clinical Medical Science, China Three Gorges University, Yichang 443000, China.
Department of Family Medicine, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Biomed Pharmacother. 2024 Feb;171:116152. doi: 10.1016/j.biopha.2024.116152. Epub 2024 Jan 15.
Urothelial carcinoma (UC) is a prevalent malignant tumor involving the urinary system. Although there are various treatment modalities, including surgery, chemotherapy, and immune checkpoint inhibitor (ICI) therapy, some patients experience disease recurrence and metastasis with poor prognosis and dismal long-term survival. Antibody-drug conjugates (ADCs), which combine the targeting ability of antibody drugs with the cytotoxicity of chemotherapeutic drugs, have recently emerged as a prominent research focus in the development of individualized precision cancer therapy. Although ADCs have improved the overall response rate in patients with UC, their effectiveness remains limited. Currently, ADC-based combination therapies, particularly ADC combined with ICIs, have demonstrated promising efficacy. This combination approach has advanced the treatment of UC, exhibiting the potential to become the standard first-line therapy for advanced UC in the future. This article reviewed clinical trials involving ADC-based combination therapy for UC and discussed the possible challenges and future perspectives to provide guidance for the clinical treatment of UC.
尿路上皮癌（UC）是一种常见的泌尿系统恶性肿瘤。尽管有多种治疗方法，包括手术、化疗和免疫检查点抑制剂（ICI）治疗，但一些患者仍会出现疾病复发和转移，预后较差，长期生存情况不佳。抗体药物偶联物（ADC）是一种将抗体药物的靶向能力与化疗药物的细胞毒性相结合的新型药物，是个体化精准癌症治疗开发中的一个重要研究热点。虽然 ADC 提高了 UC 患者的总体反应率，但疗效仍有限。目前，基于 ADC 的联合治疗方法，特别是 ADC 与 ICI 的联合治疗，已显示出良好的疗效。这种联合治疗方法推进了 UC 的治疗，有望成为未来晚期 UC 的标准一线治疗方法。本文综述了 UC 基于 ADC 的联合治疗的临床试验，并讨论了可能存在的挑战和未来展望，为 UC 的临床治疗提供指导。
